Stem cell and gene therapies for diabetes mellitus.
In this Perspectives article, we comment on the progress in experimental stem cell and gene therapies that might one day become a clinical reality for the treatment of patients with diabetes mellitus. Research on the ability of human embryonic stem cells to differentiate into islet cells has defined the developmental stages and transcription factors involved in this process. However, the clinical applications of human embryonic stem cells are limited by ethical concerns, as well as the potential for teratoma formation. As a consequence, alternative forms of stem cell therapies, such as induced pluripotent stem cells and bone marrow-derived mesenchymal stem cells, have become an area of intense study. Finally, gene therapy shows some promise for the generation of insulin-producing cells. Here, we discuss two of the most frequently used approaches: in vitro gene delivery into cells which are then transplanted into the recipient and direct delivery of genes in vivo.
Calne
Roy Y
RY
Department of Medicine, Strangeways Research Laboratory, 2 Wort's Causeway, Cambridge CB1 8RN, UK. calne@hermes.cam.ac.uk
Gan
Shu Uin
SU
Lee
Kok Onn
KO
D000818:Animals; D003920:Diabetes Mellitus / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D033581:Stem Cell Transplantation / Q000379:methods*